340 related articles for article (PubMed ID: 32476261)
41. Is COVID-19 infection more severe in kidney transplant recipients?
Caillard S; Chavarot N; Francois H; Matignon M; Greze C; Kamar N; Gatault P; Thaunat O; Legris T; Frimat L; Westeel PF; Goutaudier V; Jdidou M; Snanoudj R; Colosio C; Sicard A; Bertrand D; Mousson C; Bamoulid J; Masset C; Thierry A; Couzi L; Chemouny JM; Duveau A; Moal V; Blancho G; Grimbert P; Durrbach A; Moulin B; Anglicheau D; Ruch Y; Kaeuffer C; Benotmane I; Solis M; LeMeur Y; Hazzan M; Danion F;
Am J Transplant; 2021 Mar; 21(3):1295-1303. PubMed ID: 33259686
[TBL] [Abstract][Full Text] [Related]
42. IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.
Kang S; Tanaka T; Inoue H; Ono C; Hashimoto S; Kioi Y; Matsumoto H; Matsuura H; Matsubara T; Shimizu K; Ogura H; Matsuura Y; Kishimoto T
Proc Natl Acad Sci U S A; 2020 Sep; 117(36):22351-22356. PubMed ID: 32826331
[TBL] [Abstract][Full Text] [Related]
43. The COVIRL002 Trial-Tocilizumab for management of severe, non-critical COVID-19 infection: A structured summary of a study protocol for a randomised controlled trial.
Cotter A; Wallace D; McCarthy C; Feeney E; O'Neill L; Stack J; McCarthy G; Hussain R; Alvarez Barco E; Doran P; Mallon P
Trials; 2020 Sep; 21(1):758. PubMed ID: 32883328
[TBL] [Abstract][Full Text] [Related]
44. Breakthrough COVID-19 after SARS-CoV-2 vaccination in solid organ transplant recipients: An analysis of symptomatic cases and monoclonal antibody therapy.
Yetmar ZA; Bhaimia E; Bierle DM; Ganesh R; Razonable RR
Transpl Infect Dis; 2022 Apr; 24(2):e13779. PubMed ID: 34932874
[TBL] [Abstract][Full Text] [Related]
45. Early use of tocilizumab in solid organ transplant recipients with COVID-19: A retrospective cohort study in Saudi Arabia.
Yamani AH; Alraddadi BM; Almaghrabi RS; Amer AA; Mehdawi FS; Al-Hamzi MA; Aldajani MS; Alattas MS; Elsaed Ramadan AM; Wali GY; Alshukairi AN; Al Mutair A
Immun Inflamm Dis; 2022 Mar; 10(3):e587. PubMed ID: 35029324
[TBL] [Abstract][Full Text] [Related]
46. COVID-19 Therapeutics for Solid Organ Transplant Recipients; 6 Months Into the Pandemic: Where Are We Now?
Avery RK
Transplantation; 2021 Jan; 105(1):56-60. PubMed ID: 33141805
[TBL] [Abstract][Full Text] [Related]
47. COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul.
Demir E; Uyar M; Parmaksiz E; Sinangil A; Yelken B; Dirim AB; Merhametsiz O; Yadigar S; Atan Ucar Z; Ucar AR; Demir ME; Mese M; Akin EB; Garayeva N; Safak S; Oto OA; Yazici H; Turkmen A
Transpl Infect Dis; 2020 Oct; 22(5):e13371. PubMed ID: 32657540
[TBL] [Abstract][Full Text] [Related]
48. Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drug-Drug Interactions.
Elens L; Langman LJ; Hesselink DA; Bergan S; Moes DJAR; Molinaro M; Venkataramanan R; Lemaitre F
Ther Drug Monit; 2020 Jun; 42(3):360-368. PubMed ID: 32304488
[TBL] [Abstract][Full Text] [Related]
49. SARS-CoV-2 in Solid Organ Transplant Recipients: A Structured Review of 2020.
Quante M; Brake L; Tolios A; Della Penna A; Steidle C; Gruendl M; Grishina A; Haeberle H; Guthoff M; Tullius SG; Königsrainer A; Nadalin S; Löffler MW
Transplant Proc; 2021 Oct; 53(8):2421-2434. PubMed ID: 34551880
[TBL] [Abstract][Full Text] [Related]
50. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
[TBL] [Abstract][Full Text] [Related]
51. Sarilumab versus standard of care for the early treatment of COVID-19 pneumonia in hospitalized patients: SARTRE: a structured summary of a study protocol for a randomised controlled trial.
Caballero Bermejo AF; Ruiz-Antorán B; Fernández Cruz A; Diago Sempere E; Callejas Díaz A; Múñez Rubio E; Avendaño-Solá C; Ramos Martínez A; Sancho López A;
Trials; 2020 Sep; 21(1):794. PubMed ID: 32938496
[TBL] [Abstract][Full Text] [Related]
52. COVID-19 in Heart Transplant Recipients: A Multicenter Analysis of the Northern Italian Outbreak.
Bottio T; Bagozzi L; Fiocco A; Nadali M; Caraffa R; Bifulco O; Ponzoni M; Lombardi CM; Metra M; Russo CF; Frigerio M; Masciocco G; Potena L; Loforte A; Pacini D; Faggian G; Onorati F; Sponga S; Livi U; Iacovoni A; Terzi A; Senni M; Rinaldi M; Boffini M; Marro M; Jorgji V; Carrozzini M; Gerosa G
JACC Heart Fail; 2021 Jan; 9(1):52-61. PubMed ID: 33309578
[TBL] [Abstract][Full Text] [Related]
53. Outcomes of critically ill solid organ transplant patients with COVID-19 in the United States.
Molnar MZ; Bhalla A; Azhar A; Tsujita M; Talwar M; Balaraman V; Sodhi A; Kadaria D; Eason JD; Hayek SS; Coca SG; Shaefi S; Neyra JA; Gupta S; Leaf DE; Kovesdy CP;
Am J Transplant; 2020 Nov; 20(11):3061-3071. PubMed ID: 32844546
[TBL] [Abstract][Full Text] [Related]
54. COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Addeo A; Obeid M; Friedlaender A
J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32434788
[TBL] [Abstract][Full Text] [Related]
55. COVID-19 and solid organ transplantation: Finding the right balance.
Opsomer R; Kuypers D
Transplant Rev (Orlando); 2022 Jul; 36(3):100710. PubMed ID: 35809422
[TBL] [Abstract][Full Text] [Related]
56. COVID-19 in transplant recipients: The Spanish experience.
Coll E; Fernández-Ruiz M; Sánchez-Álvarez JE; Martínez-Fernández JR; Crespo M; Gayoso J; Bada-Bosch T; Oppenheimer F; Moreso F; López-Oliva MO; Melilli E; Rodríguez-Ferrero ML; Bravo C; Burgos E; Facundo C; Lorenzo I; Yañez Í; Galeano C; Roca A; Cabello M; Gómez-Bueno M; García-Cosío M; Graus J; Lladó L; de Pablo A; Loinaz C; Aguado B; Hernández D; Domínguez-Gil B;
Am J Transplant; 2021 May; 21(5):1825-1837. PubMed ID: 33098200
[TBL] [Abstract][Full Text] [Related]
57. Outcome of COVID-19 patients with use of Tocilizumab: A single center experience.
Zain Mushtaq M; Bin Zafar Mahmood S; Jamil B; Aziz A; Ali SA
Int Immunopharmacol; 2020 Nov; 88():106926. PubMed ID: 32889236
[TBL] [Abstract][Full Text] [Related]
58. Rapid and Impressive Response to a Combined Treatment with Single-Dose Tocilizumab and NIV in a Patient with COVID-19 Pneumonia/ARDS.
Cascella M; Mauro I; De Blasio E; Crispo A; Del Gaudio A; Bimonte S; Cuomo A; Ascierto PA
Medicina (Kaunas); 2020 Jul; 56(8):. PubMed ID: 32727107
[TBL] [Abstract][Full Text] [Related]
59. Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic.
Reuken PA; Rauchfuss F; Albers S; Settmacher U; Trautwein C; Bruns T; Stallmach A
Am J Transplant; 2020 Nov; 20(11):3042-3050. PubMed ID: 32515125
[TBL] [Abstract][Full Text] [Related]
60. A Phase 3 Open-label, Randomized, Controlled Study to Evaluate the Efficacy and Safety of Intravenously Administered Ravulizumab Compared with Best Supportive Care in Patients with COVID-19 Severe Pneumonia, Acute Lung Injury, or Acute Respiratory Distress Syndrome: A structured summary of a study protocol for a randomised controlled trial.
Smith K; Pace A; Ortiz S; Kazani S; Rottinghaus S
Trials; 2020 Jul; 21(1):639. PubMed ID: 32660611
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
